: Musculoskeletal disorders (MSDs) affect about one out of three adults in the U.S., are the leading cause of adult disability, and have total costs exceeding $100 billion/year. For most of the past two decades, treatment of arthritis and osteoporosis remained largely stagnant. Since 1998, over 15 new treatments have been FDA approved for MSDs, including novel biological response modifiers. Despite significant efficacy in clinical trials, questions and concerns persist about the safety, comparative effectiveness, and costs (biologics >$10,000 annually/patient) of some of these new agents. During its six years of past AHRQ funding, the UAB CERTs conducted over 30 projects creating new knowledge and products, disseminating research and education findings, and improving public health. Our main objective of this new application is to seize the momentum of our past success to better promote the safe and effective use of MSD therapeutics. Given the rising burden of MSD in an aging society and the rapidly advancing efficacious yet costly therapeutic options with risk of serious adverse events, this objective is both timely and very important.
The specific aims of the proposed Deep South Musculoskeletal (DSM) CERTs are to: 1) Improve safety and effectiveness of MSD therapeutics through four demonstration projects that effectively build on our major research domains of safety and effectiveness evidence generation and translating research into practice: (a) The Alabama NSAID Patient Safety Study, Phase II: Reducing Disparities in Risk Assessment and Communication;(b) Improving Osteoporosis Care for High-Risk Home Health Patients by a High-intensity Intervention;(c) Defining Serious Adverse Events from Biologic Therapies;and (d) Osteonecrosis of the Jaw: An Emerging Threat for Bisphosphonate Users;2) Educate health care practitioners, insurers, and policy makers while broadening the public health impact of our research and educational portfolio about musculoskeletal therapeutics;and 3) In cooperation with AHRQ, other CERTs, and our network of partners, and building upon the themes, experience, and investigator talent pool of our CERTs, develop seed projects into full proposals that will be submitted to external funding agencies for peer review. We have expanded our group of experienced senior and talented junior investigators, our dedicated staff, and a rich network of regional and national partners. Through our Administrative Unit, a Methods Core containing Communications, Economics and Biostatistical Components, and an Education and Dissemination Core we provide the necessary infrastructure, a clear organizational plan, and proven research/educational expertise to successful undertake this multi-disciplinary program. Our subtheme of risk communication to patients and/or healthcare providers runs through all four demonstration projects, the seed projects, and the Cores. In recognition of the special relevance of eliminating racial/ethnic disparities in MSD therapeutics, we have chosen the name DSM CERTs, reflecting on our region's past, and demonstrating our commitment to further improve regional and national MSD health care quality.

National Institute of Health (NIH)
Agency for Healthcare Research and Quality (AHRQ)
Research Demonstration--Cooperative Agreements (U18)
Project #
Application #
Study Section
Special Emphasis Panel (ZHS1-HSR-O (01))
Program Officer
Nourjah, Parivash
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
van den Bogert, Cornelis A; Miller, Michael J; Cobaugh, Daniel J et al. (2017) Screening Questions for Nonsteroidal Anti-inflammatory Drug Risk Knowledge. J Patient Saf 13:217-222
Safford, Monika M; Barasch, Andrei; Curtis, Jeffrey R et al. (2014) Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration. J Clin Rheumatol 20:357-62
Sattui, Sebastian E; Singh, Jasvinder A; Gaffo, Angelo L (2014) Comorbidities in patients with crystal diseases and hyperuricemia. Rheum Dis Clin North Am 40:251-78
Curtis, J R; Yang, S; Patkar, N M et al. (2014) Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:990-7
Curtis, Jeffrey R; Sharma, Pradeep; Arora, Tarun et al. (2013) Physicians' explanations for apparent gaps in the quality of rheumatology care: results from the US Medicare Physician Quality Reporting System. Arthritis Care Res (Hoboken) 65:235-43
Ritchie, Christine S; Hearld, Kristine R; Gross, Alden et al. (2013) Measuring symptoms in community-dwelling older adults: the psychometric properties of a brief symptom screen. Med Care 51:949-55
Mudano, Amy S; Gary, Lisa C; Oliveira, Ana L et al. (2013) Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: feasibility, satisfaction, and sample size. Patient Prefer Adherence 7:517-23
Singh, Jasvinder A (2013) Racial and gender disparities among patients with gout. Curr Rheumatol Rep 15:307
Curtis, Jeffrey R; Yun, Huifeng; Lange, Jeff L et al. (2012) Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data. Arthritis Care Res (Hoboken) 64:1855-63
Curtis, Jeffrey R; Yun, Huifeng; Matthews, Robert et al. (2012) Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken) 64:1054-60

Showing the most recent 10 out of 32 publications